Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acquired aplastic anemia involves immune-mediated bone marrow destruction.
• Standard immunosuppressive therapies can be limited by residual stem cell numbers.
• Eltrombopag, a thrombopoietin-receptor agonist, has shown efficacy in refractory aplastic anemia.

Purpose of the Study:

• To evaluate the efficacy and safety of combining standard immunosuppressive therapy with eltrombopag in previously untreated severe aplastic anemia patients.
• To compare hematologic response rates with historical data.

Main Methods:

• A prospective phase 1-2 study enrolled 92 patients with severe aplastic anemia.
• Patients were divided into three cohorts based on eltrombopag initiation timing and duration.
• Primary outcome was complete hematologic response at 6 months; secondary outcomes included overall response, survival, and relapse.

Main Results:

• Complete response rates at 6 months were 33% (cohort 1), 26% (cohort 2), and 58% (cohort 3).
• Overall response rates were 80%, 87%, and 94%, respectively, exceeding historical rates (10% complete, 66% overall).
• Survival rate was 97% at 2-year follow-up, with noted increases in bone marrow cellularity and hematopoietic progenitors.

Conclusions:

• Combining eltrombopag with immunosuppressive therapy significantly increases hematologic response rates in severe aplastic anemia.
• This combination therapy demonstrates superior efficacy compared to historical treatment cohorts.
• The addition of eltrombopag appears safe, with severe rashes being the main adverse event.